537 related articles for article (PubMed ID: 33198356)
1. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Ahn HK; Lee YH; Koo KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198356
[TBL] [Abstract][Full Text] [Related]
2. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
3. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
4. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Hankinson SJ; Fam M; Patel NN
Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
[TBL] [Abstract][Full Text] [Related]
5. The anticancer potential of metformin on prostate cancer.
Zaidi S; Gandhi J; Joshi G; Smith NL; Khan SA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):351-361. PubMed ID: 30651580
[TBL] [Abstract][Full Text] [Related]
6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
7. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Sanli T; Rashid A; Liu C; Harding S; Bristow RG; Cutz JC; Singh G; Wright J; Tsakiridis T
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):221-9. PubMed ID: 20615625
[TBL] [Abstract][Full Text] [Related]
8. Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Thent ZC; Zaidun NH; Azmi MF; Senin MI; Haslan H; Salehuddin R
Curr Drug Targets; 2017; 18(6):734-750. PubMed ID: 27919208
[TBL] [Abstract][Full Text] [Related]
9. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Crawley D; Chandra A; Loda M; Gillett C; Cathcart P; Challacombe B; Cook G; Cahill D; Santa Olalla A; Cahill F; George G; Rudman S; Van Hemelrijck M
BMC Cancer; 2017 Jul; 17(1):494. PubMed ID: 28732480
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
11. Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Winters B; Plymate S; Zeliadt SB; Holt S; Zhang X; Hu E; Lin DW; Morrissey C; Wooldridge B; Gore JL; Porter MP; Wright JL
Prostate; 2015 Nov; 75(15):1694-703. PubMed ID: 26201966
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
13. Metformin and Prostate Cancer: a New Role for an Old Drug.
Whitburn J; Edwards CM; Sooriakumaran P
Curr Urol Rep; 2017 Jun; 18(6):46. PubMed ID: 28444639
[TBL] [Abstract][Full Text] [Related]
14. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
Chomanicova N; Gazova A; Adamickova A; Valaskova S; Kyselovic J
Physiol Res; 2021 Aug; 70(4):501-508. PubMed ID: 34062070
[TBL] [Abstract][Full Text] [Related]
15. Metformin and neoplasia: implications and indications.
Aljada A; Mousa SA
Pharmacol Ther; 2012 Jan; 133(1):108-15. PubMed ID: 21924289
[TBL] [Abstract][Full Text] [Related]
16. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.
Akhtar N; Syed DN; Khan MI; Adhami VM; Mirza B; Mukhtar H
Oncotarget; 2016 Jan; 7(4):3819-31. PubMed ID: 26683363
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits esophagus cancer proliferation through upregulation of USP7.
Xu Y; Lu S
Cell Physiol Biochem; 2013; 32(5):1178-86. PubMed ID: 24335168
[TBL] [Abstract][Full Text] [Related]
19. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
20. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
[Next] [New Search]